Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.42 |
| ▸ | ESR1 | P03372 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2785589 | 0.84 | AR (0.57) | TSHRARESR2ESR1 | |
| SCHEMBL805064 | 0.82 | TSHR (0.48) | TSHRARESR2ESR1CA9 | |
| SCHEMBL17679937 | 0.79 | CA2 (0.50) | ARESR2ESR1CA9CA12 | |
| SCHEMBL29473510 | 0.78 | CA9 (0.46) | ARESR2ESR1CA9CA12 | |
| SCHEMBL1697195 | 0.78 | CA9 (0.46) | ARESR2ESR1CA9CA12 | |
| SCHEMBL14173238 | 0.78 | CA12 (0.44) | TSHRARESR2ESR1CA9 | |
| SCHEMBL12287630 | 0.77 | CYP3A4 (0.41) | TSHRARESR2ESR1CYP3A4 | |
| SCHEMBL14173712 | 0.77 | AR (0.50) | ARESR2ESR1 | |
| SCHEMBL277588 | 0.76 | TSHR (0.52) | TSHRARALOX15 | |
| SCHEMBL1267080 | 0.76 | ESR2 (0.44) | ARESR2ESR1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12428370-B2 | Haloallylamine dual amine oxidase inhibitors | SYNTARA LIMITED (AU) | 2025-09-30 | — | — | US | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| CN-119968366-A | Oxadiazole derivatives, methods of preparation and use thereof in the treatment of inflammatory diseases | 西特瑞治疗有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4543875-A1 | OXADIAZOLE DERIVATIVES, PREPARATION PROCESS THEREOF AND THEIR USE IN TREATING INFLAMMATORY DISEASES | Sitryx Therapeutics Limited (GB) | 2025-04-30 | — | — | EP | disclosed |
| CN-115916337-B | Halogenated allylamine bis amine oxidase inhibitors | 法玛西斯有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-6730241-B2 | ACRYLATED POLYESTERS | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20030025104-A1 | Polymerizable composition showing liquid-crystal phase and optically anisotropic object made with the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-02-06 | — | — | US | disclosed |
| EP-1267874-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| CN-1358167-A | Polymerizable composition exhibiting liquid crystal phase and optically anisotropic body using same | DAINIPPON INK & CHEMICALS (JP) | 2002-07-10 | — | — | CN | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-1174412-A1 | POLYMERIZABLE COMPOSITION SHOWING LIQUID-CRYSTAL PHASE AND OPTICALLY ANISOTROPIC OBJECT MADE WITH THE SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2002-01-23 | — | — | EP | disclosed |
| WO-2001066098-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-09-13 | — | — | WO | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4031232-A | 1-Alkyl-2-(phenoxymethyl)-5-nitro-imidazoles and process for their manufacture | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137680-A1 | NOVEL COMPOUNDS | CCR1, CCR4, CCR3 | TSHR 3430/4885AR 2287/4885ESR2 3478/4885 |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | TSHR 2521/4885AR 1936/4885ESR2 1542/4885 |
| US-12428370-B2 | Haloallylamine dual amine oxidase inhibitors | AOC2, AOC3, AOC1 | TSHR 2376/4885AR 4435/4885ESR2 4111/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | TSHR 2521/4885AR 1936/4885ESR2 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.